Journal Article

DKFZ-2022-02629

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.

Kolwelter, J. ; Kannenkeril, D. ; Linz, P. ; Jung, S. ; Nagel, A. M.DKFZ* ; Bosch, A. ; Ott, C. ; Bramlage, P. ; Nöh, L. ; Schiffer, M. ; Uder, M. ; Achenbach, S. ; Schmieder, R. E.

2023
Springer Berlin

This record in other databases:  

Please use a persistent id in citations: doi:10.1007/s00392-022-02119-7

Abstract: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised that empagliflozin reduces tissue sodium content in patients with CHF.In a double-blind, randomised (2:1), placebo-controlled, parallel-group, clinical trial, 74 patients with NYHA class II-III CHF and an ejection fraction of 49% or less received empagliflozin 10 mg once daily or placebo for 3 months. In each patient, tissue sodium content of the lower leg was assessed non-invasively by sodium-MRI (23Na-MRI) at baseline, after 1 and 3 months of treatment.After 1 and 3 months treatment with empagliflozin (n = 48), a significant decrease in skin sodium content was observed (1 month: 22.8 ± 6.1 vs. 21.6 ± 6.0 AU, p = 0.039; 3 months: 22.9 ± 6.1 vs. 21.6 ± 6.1 AU, p = 0.013), while there was no change in muscle sodium and muscle water content. In direct comparison, the change in skin sodium content between baseline and 3 months was - 1.3 ± 3.5 AU in the empagliflozin group versus 0.6 ± 3.5 AU in the placebo group (p for between-group difference = 0.022). No significant difference regarding change in muscle sodium and in muscle water content was observed after 3 months treatment between the two groups.This trial showed a significant decrease in skin sodium content after 1 and 3 months of treatment with empagliflozin. The decrease in skin sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound tissue sodium, both reported to impair left ventricular function.NCT03128528 ( http://www.gov ).25th April 2017.

Keyword(s): Chronic heart failure ; Empagliflozin ; Magnetic resonance imaging ; SGLT2 inhibitor ; Sodium ; Tissue sodium content

Note: 2023 Jan;112(1):134-144

---

Contributing Institute(s):

1. E020 Med. Physik in der Radiologie (E020)

Research Program(s):

1. 315 - Bildgebung und Radioonkologie (POF4-315) (POF4-315)

Appears in the scientific report 2022

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Essential Science Indicators ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---